Pharmaceuticals (Basel). 2025 Aug 6;18(8):1167. doi: 10.3390/ph18081167.
ABSTRACT
Objectives: Saccharomyces boulardii CNCM I-745, a probiotic yeast, is effectively used for the treatment of acute diarrhea as well as for the prevention and treatment of traveller's diarrhea and diarrhea under tube feeding. The underlying mechanisms are not fully elucidated. Both antitoxic and regulatory effects on the intestinal barrier, mediated either by the yeast or yeast-derived substrates, have been discussed. Methods: To examine the effects of Saccharomyces boulardii released substrates (S.b.S) on gastrointestinal (GI) barrier function, a murine small intestinal organoid cell model under stress was used. Stress was induced by lipopolysaccharide (LPS) exposure or withdrawal of growth factors from cell culture medium (GFRed). Stressed organoids were treated with S.b.S (200 µg/mL), and markers of GI barrier and inflammatory response were assessed. Results: GFRed-induced stress was characterized by disturbances in selected tight junction (TJ) (p p Muc) formation (p Muc2 (from 0.22 to 0.97-fold change, p Ocln) (from 0.37 to 3.5-fold change, p Cldn)7 expression (from 0.13 ± 0.066-fold change, p Muc1, Cldn2, Cldn5, and junctional adhesion molecule A (JAM-A) expression (all p Nod)2- (from 44.5 to 0.51, p Mmp)7-dependent activation (from 28.3 to 0.02875 ± 0.0044 ** p Myd88) (p Tnfα) (p IL)-6 (p IL-1β (p Conclusions: Our data provide new insights into the molecular mechanisms by which Saccharomyces boulardii CNCM I-745-derived secretome attenuates inflammatory responses and restores GI barrier function in small intestinal organoids.
PMID:40872558 | PMC:PMC12389396 | DOI:10.3390/ph18081167